Analysts at StockNews.com started coverage on shares of 22nd Century Group (NASDAQ:XXII – Get Free Report) in a report issued on Sunday. The firm set a “sell” rating on the biotechnology company’s stock.
22nd Century Group Stock Performance
Shares of 22nd Century Group stock opened at $0.10 on Friday. 22nd Century Group has a twelve month low of $0.09 and a twelve month high of $9.07. The firm has a market capitalization of $869,830.80, a PE ratio of 0.00 and a beta of 1.39. The firm’s 50-day moving average price is $0.32 and its 200 day moving average price is $0.86.
22nd Century Group (NASDAQ:XXII – Get Free Report) last announced its earnings results on Tuesday, August 13th. The biotechnology company reported ($0.36) EPS for the quarter. The firm had revenue of $7.95 million for the quarter. 22nd Century Group had a negative net margin of 275.12% and a negative return on equity of 380.39%.
Institutional Trading of 22nd Century Group
About 22nd Century Group
22nd Century Group, Inc, a tobacco products company, engages in the sale and distribution of its own proprietary new reduced nicotine tobacco products. The company offers reduced nicotine content tobacco plants and very low nicotine combustible cigarette products. It also provides contract manufacturing services for conventional combustible tobacco products for third-party brands.
Featured Articles
- Five stocks we like better than 22nd Century Group
- Investing In Automotive Stocks
- Misses and Beats: 3 Stocks That Are Moving Markets Right Now
- The 3 Best Retail Stocks to Shop for in August
- Cisco on the Rise: AI Potential and Analyst Upgrades Drive Gains
- Most active stocks: Dollar volume vs share volume
- MarketBeat Week in Review – 10/14 – 10/18
Receive News & Ratings for 22nd Century Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 22nd Century Group and related companies with MarketBeat.com's FREE daily email newsletter.